N/A N=12 A Transition of Care Model From Hospital to Community for Hispanic/Latino Adult Patients With Diabetes.
Diabetes Mellitus
Primary: Emergency Department (ED) Visits Within 30 Days Post Discharge — 0 emergency department visits
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers
Healthy
Primary: Maximum Safinamide Plasma Concentration (Cmax) — 411.5; 792.1; 465.0; 825.3 nanogram/milliliter (ng/mL)
Phase 3 N=100 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Progression-Free Survival (PFS) — 12.32; 22.57 months — p=<.0001
N/A N=30 The Effects of Angle Kappa on Clinical Outcomes With the PanOptix Intraocular Lens
Pseudophakia
Primary: Effect of Angle Kappa in Visual Disturbances — 4; 4; 5; 1 Participants
N/A N=11 Blue Light Phototherapy
Grover's Disease · Psoriasis Vulgaris
Primary: Efficacy of Blue Light Therapy for Patients With Grover's Disease — 27; 6 lesion count
N/A N=191 UK Ibrance Patient Program (IPP) Study
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
Primary: Percentage of Participants According to Treatment Lines — 72; 16; 10; 2 Percentage of participants
Phase 1 N=20 Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants
Healthy Volunteers
Primary: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Midazolam — 24.2; 50.7 Nanogram Hours per Milliliter…
Phase 3 N=1,405 Randomized Trial in Adult Participants With Acute Migraines
Migraine
Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 23.6; 14.9 Percentage of participants — p=<0.0001
N/A N=20 CoV-PICS: A Virtual Post-ICU Clinic
Post ICU Syndrome
Primary: Acceptance With COVID-19 Virtual Post Intensive Care Syndrome (CoV-PICS) Visits - AIM — 4.8 score on a scale
Phase 2 N=113 Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
Locally Advanced or Metastatic Urothelial Bladder Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC) — 24.0 Percentage of participants — p=< 0.0001
N/A N=283 Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Percentage of Participants With Early Onset Primary Adverse Events (PAEs): Atrio-esophageal Fistula and Pulmonary Vein (PV) Stenosis — 0; 0 Percentage of Participants
Phase 3 N=393 Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)
Asthma
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 54.5 percentage of participants
Phase 1 N=97 First in Human Study of M4344 in Participants With Advanced Solid Tumors
Solid Tumor · Advanced Solid Tumor
Primary: Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 2; 1; 2; 1 Participants
N/A N=162 Clinical Assessment of Two Reusable Silicone Hydrogel Contact Lenses
Refractive Errors
Primary: Least Squares Mean Distance Visual Acuity With Study Lenses at Day 30 — -0.07; -0.07 logMAR
N/A N=99 A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma
Multiple Myeloma · Non-Hodgkin's Lymphoma
Primary: Number of Participants With Grade 3 or Higher Diarrhea GI Toxicity — 18; 21 Participants